Bloom Burton Forecasts BioSyent's FY2025 Earnings (CVE:RX)

BioSyent Inc. (CVE:RX - Free Report) - Investment analysts at Bloom Burton lowered their FY2025 EPS estimates for shares of BioSyent in a research note issued on Tuesday, May 20th. Bloom Burton analyst D. Martin now forecasts that the company will earn $0.75 per share for the year, down from their prior forecast of $0.81. The consensus estimate for BioSyent's current full-year earnings is $0.69 per share.

BioSyent Price Performance

Shares of CVE:RX traded up C$0.05 during midday trading on Thursday, reaching C$12.00. 3,924 shares of the company's stock were exchanged, compared to its average volume of 4,711. The company's 50 day simple moving average is C$10.85 and its two-hundred day simple moving average is C$11.07. The firm has a market capitalization of C$137.25 million, a PE ratio of 19.48 and a beta of 0.93. BioSyent has a 12 month low of C$8.97 and a 12 month high of C$12.13. The company has a debt-to-equity ratio of 2.90, a quick ratio of 6.91 and a current ratio of 3.92.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.